Leverage scientific, clinical, and regulatory expertise to de-risk drug development, from the outset
Follow the most efficient regulatory pathway by proactively addressing all facets of drug development. By understanding the intricacies of scientific, clinical and regulatory requirements, you can identify any potential risks earlier, and implement appropriate mitigation strategies.
In the early phases of product development, our global team of ex-regulators and industry specialists provide:
Regulatory intelligence
Regulatory intelligence is a prerequisite to stay informed about the evolving global regulatory landscape. We remain fully up-to-date with the latest changes to FDA and EMA regulations and guidelines, to support our clients to enhance their drug development strategies and navigate the complexities of regulatory requirements, from the early stages of development.
Strategic regulatory advice
With tailored approaches for asset development, from bench to patient, we utilize our teams’ expertise and regulatory intelligence to develop robust regulatory strategies that align with current best practices, including Good Clinical Practice (GCP). Our goal is to enable clients to make informed decisions, navigate the evolving regulatory environment and achieve successful drug development outcomes.
Regulatory authority/agency consulting and engagement
We understand the critical importance of creating a positive first impression with regulatory authorities, with early and frequent engagement. By formulating an optimal approach to engage with authorities, our team of ex-regulators can navigate their expectations and requirements.
Regulatory gap assessment
With comprehensive regulatory gap assessment services, our team evaluates clinical, non-clinical and CMC data, comparing it with national and international regulatory requirements and guidelines. We proactively engage with authorities to check the suitability of existing data, proposed clinical studies and forthcoming marketing approvals with the aim of:
- Identifying any gaps in data
- Defining crucial points for discussions with regulatory authorities
- Establishing a solid foundation for the development plan of your product
Target product profile (TPP) consulting
Define the TPP for your product with guidance on considerations including intended use, patient population, desired efficacy and safety profile, dosage form and route of administration.
Product development plans
With a track record of delivering well-crafted and accurate product development plans, we provide comprehensive support across non-clinical, CMC, and clinical development. Our expertise spans the drug development continuum including study design, regulatory compliance, protocol development, and patient recruitment so we understand the criticality of getting it right. By leveraging our holistic approach, we aim to minimize risk and optimize the potential for success so your product development plan aligns with regulatory requirements and your corporate goals.
A trusted partner
Our dedication to patients and the pursuit of safe and effective drug development is our purpose. With a team of 1,300+ regulatory specialists, including former regulators from agencies across the world, Parexel has the knowledge, insights and technology-enabled processes to accelerate and streamline your drug development journey. With experience in more than 110 countries, we provide strategic regulatory advice, proactively identify and mitigate risks and navigate the ever-evolving regulatory landscape. Our deep therapeutic insight and proven track record make us a reliable partner for achieving regulatory success.
Our experts
Mwango Kashoki, M.D., M.P.H.
Head, Regulatory Sciences
Tala H. Fakhouri, Ph.D., M.P.H.
Chief AI & Regulatory Strategy Officer
Sinan Sarac, M.D., Ph.D., M.Sc.
Senior Vice President, Head of Regulatory Science - Oncology
Pengfei Song, Ph.D.
Senior Vice President, Regulatory Strategy
Aaron Sosa, M.D.
Vice President, Technical, Regulatory Consulting
Bernardo Haddock Lobo Goulart, M.D.
Vice President - Technical, Regulatory Strategy
Kurt Brorson, Ph.D.
Vice President, Technical, Regulatory Consulting
Our experts
Mwango Kashoki, M.D., M.P.H.
Head, Regulatory Sciences
Tala H. Fakhouri, Ph.D., M.P.H.
Chief AI & Regulatory Strategy Officer
Sinan Sarac, M.D., Ph.D., M.Sc.
Senior Vice President, Head of Regulatory Science - Oncology
Pengfei Song, Ph.D.
Senior Vice President, Regulatory Strategy
Aaron Sosa, M.D.
Vice President, Technical, Regulatory Consulting
Bernardo Haddock Lobo Goulart, M.D.
Vice President - Technical, Regulatory Strategy
Browse our latest regulatory insights
Want to hear from our experts on the latest industry topics? Visit our Insights Center to read, watch, and listen.
Related Insights
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to Global: Designing Data that Travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Blog
Accelerating first-in-human studies: Why the FDA’s Expedited IND pilot signals a new era for early development
Jul 6, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
Case Study
Case study: Repositioning first-in-human development at speed
Jun 8, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
Playbook
JCA in the EU: A roadmap for health technology developers
May 15, 2026
Blog
Understanding the FDA’s latest guidance on safety assessment of genome editing therapies using next-generation sequencing
Apr 23, 2026
Blog
Comparing joint clinical assessment (JCA) and joint scientific consultation (JSC) pathways for medicinal products and medical devices/in vitro diagnostics
Apr 22, 2026
Blog
EU JCA: Two early takeaways for sponsors preparing for JCA from Swedish authorities (TLV and SBU)
Apr 13, 2026
Blog
New FDA guidance on validation of new approach methodologies (NAMs): What you need to know
Apr 8, 2026
Blog
FDA novel oncology drug approvals in 2025: Trends and strategic insights for developers
Mar 31, 2026
Blog
From FDA 483 to Warning Letter: A practical guide with compliance process explained
Mar 30, 2026
CTB Blog
FDA’s new biosimilar guidance explained: Key changes in reference product requirements
Mar 19, 2026
CTB Blog
Harmonizing UK and EU CTA submissions: Practical strategies from EU-CTR experience
Mar 19, 2026
Related Insights
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to Global: Designing Data that Travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Blog
Accelerating first-in-human studies: Why the FDA’s Expedited IND pilot signals a new era for early development
Jul 6, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
Case Study
Case study: Repositioning first-in-human development at speed
Jun 8, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
Playbook
JCA in the EU: A roadmap for health technology developers
May 15, 2026
Blog
Understanding the FDA’s latest guidance on safety assessment of genome editing therapies using next-generation sequencing
Apr 23, 2026
Blog
Comparing joint clinical assessment (JCA) and joint scientific consultation (JSC) pathways for medicinal products and medical devices/in vitro diagnostics
Apr 22, 2026
Blog
EU JCA: Two early takeaways for sponsors preparing for JCA from Swedish authorities (TLV and SBU)
Apr 13, 2026
Blog
New FDA guidance on validation of new approach methodologies (NAMs): What you need to know
Apr 8, 2026
Blog
FDA novel oncology drug approvals in 2025: Trends and strategic insights for developers
Mar 31, 2026
Blog
From FDA 483 to Warning Letter: A practical guide with compliance process explained
Mar 30, 2026
CTB Blog
FDA’s new biosimilar guidance explained: Key changes in reference product requirements
Mar 19, 2026
CTB Blog
Harmonizing UK and EU CTA submissions: Practical strategies from EU-CTR experience
Mar 19, 2026